

The Moisture Status of the Skin of the Feet Assessed by the Visual Test Neuropad Correlates with Foot Ulceration in Diabetes

NICHOLAS TENTOLOURIS, MD, CHRISTINA VOULGARI, MD, STAVROS LIATIS, MD, ALEXANDER KOKKINOS, MD, IOANNA ELEFThERIADOU, MD, KONSTANTINOS MAKRILAKIS, MD, KYRIAKI MARINOU, MD, NICHOLAS KATSILAMBROS, MD

First Department of Propaedeutic Medicine, Laiko General Hospital, Athens University Medical School, Athens, Greece

Running title: Dry skin and foot ulceration

Corresponding author:

Nicholas Tentolouris
Email: ntentol@med.uoa.gr

Submitted 1 November 2009 and accepted 28 January 2010.

This is an uncopyedited electronic version of an article accepted for publication in *Diabetes Care*. The American Diabetes Association, publisher of *Diabetes Care*, is not responsible for any errors or omissions in this version of the manuscript or any version derived from it by third parties. The definitive publisher-authenticated version will be available in a future issue of *Diabetes Care* in print and online at <http://care.diabetesjournals.org>.

Objective -To examine the association between the moisture status of the skin of the feet with foot ulceration (FU) in subjects with diabetes.

Research design and methods - A total of 379 subjects with diabetes were examined. Assessment of peripheral neuropathy was based on neuropathy symptom score, neuropathy disability score, vibration perception threshold and the 10 g-monofilament perception. The moisture status of the skin of the feet was assessed using the visual test Neuropad.

Results - Patients with FU had more severe peripheral neuropathy and more often an abnormal Neuropad response. Multivariate logistic regression analysis demonstrated that the odds of FU increased with measures of neuropathy but increased also with an abnormal Neuropad response.

Conclusions - An abnormal Neuropad response correlates with FU in subjects with diabetes. This finding, if confirmed prospectively, suggests that the Neuropad test may be included in the screening tests for the prediction of FU.

Damage of the peripheral sympathetic nerves results in sudomotor dysfunction which manifests as dry skin of the feet and may result in callus and/or fissure formation and eventually in foot ulceration (FU) (1,2). The American Diabetes Association (ADA) recommends examination of sudomotor function for the detection of diabetic neuropathies (3); however, the lack of specific equipment has restricted the study of sudomotor function and its contribution to FU. The Neuropad test (miro Verbandstoffe, Wiehl-Drabenderhöhe, Germany) is a novel visual test for the assessment of the moisture status of the skin of the feet (4,5). The research hypothesis we tested herein was that an abnormal Neuropad response may be associated with FU in subjects with diabetes.

RESEARCH DESIGN AND METHODS

A total of 379 adult subjects were recruited in this study. Exclusion criteria were age >75 years, ankle-brachial-pressure index (ABI)<0.5, estimated creatinine clearance rate using the formula of Cockcroft-Gault <30 ml/min, amputation, significant foot swelling or infection, and causes of neuropathy other than diabetes. The demographic and clinical characteristics of the participants are shown in Table 1.

Assessment for peripheral neuropathy (PN) was based on symptoms (neuropathy symptom score; NSS) and signs (neuropathy disability score; NDS), as described previously (6). Moreover, we assessed vibration perception threshold (VPT) using a biothesiometer (Biomedical Instruments, Newbury, OH, USA) and the 10 g Semmes-Weinstein monofilament (Bailey Instruments Ltd, Manchester, UK) perception. Monofilament was applied three times on three plantar sites (under

the great toe, first and fifth metatarsal heads) (7,8). Inability to perceive the monofilament at any site was considered abnormal. The Neuropad was applied for 10 min under the first metatarsal head in the sitting position at both feet and evaluated as normal (pink color) or abnormal (blue color or any other combination of colors) (4,5). Peripheral artery disease (PAD) was diagnosed in the presence of any of the following: history of intermittent claudication or revascularization procedure at the leg arteries; diminished or non-palpable pedal pulses; and ABI <0.9.

Differences between the studied groups were tested using parametric or non-parametric methods according to the specific indications, while a χ^2 test was used to compare categorical data. Univariate and multivariate logistic regression analyses (stepwise backward method) were performed to look for associations between the studied parameters with FU. The area under the receiver operating characteristic (ROC) curve of various established risk factors for FU and of the Neuropad test was calculated. The area under the ROC curve indicates how informative a test for the prediction of FU is. *P* values <0.05 were considered statistically significant.

RESULTS

Subjects with FU were mostly men, had longer diabetes duration, worse glycemic control and more often PN and PAD than subjects without FU. The values of the NSS, NDS, and VPT were higher, while monofilament insensation and an abnormal Neuropad result were more often documented in patients with FU (Table 1). The Neuropad result was not different between patients with

neuropathic and neuro-ischemic ulcers ($P=0.30$).

Univariate logistic regression analysis showed that the odds of FU increased with male gender, longer duration of diabetes, worse diabetes control, increasing NSS, NDS and VPT, monofilament insensitation, presence of PAD and abnormal Neuropad response. Multivariate logistic regression analysis after adjustment for age, gender, duration of diabetes, A1C, NSS, and PAD status demonstrated that the odds of FU increased with higher NDS, VPT and monofilament insensitation as well as with an abnormal Neuropad result (Table 1).

The area (\pm SE) under the ROC curve for the identification of patients with FU of $VPT \geq 25$ vs. < 25 Volts was 0.76 ± 0.02 ($P < 0.001$; sensitivity 85.4%; specificity 67.6%), of $NDS \geq 6$ vs. < 6 was 0.76 ± 0.02 ($P < 0.001$; sensitivity 75.7%; specificity 77.8%), of monofilament result (insensitation vs. sensation) was 0.72 ± 0.03 ($P < 0.001$; sensitivity 57.4%; specificity 86.3%), and of the Neuropad result (abnormal vs. normal) was 0.71 ± 0.03 ($P < 0.001$; sensitivity 97.1%; specificity 49.3%). The area under the ROC curve of Neuropad testing did not differ significantly from that of VPT, NDS and monofilament examination. No adverse events were observed from the Neuropad use.

CONCLUSIONS

This study has shown that dryness of the skin of the feet correlates with FU. Subclinical sudomotor dysfunction can be detected early in diabetes, even in subjects with normal nerve conduction velocities (9). We showed that dryness of the skin of the feet was detected in 95% of the patients with FU using the Neuropad test. These findings agree with previous data showing sudomotor

dysfunction assessed with the sympathetic skin response in the vast majority of patients with FU (10).

Noteworthy, the comparison of the values of the areas under the ROC curves demonstrated that the results obtained by Neuropad testing are as informative as those obtained by determination of other neurological modalities commonly used for the prediction of FU like VPT, NDS and monofilament testing.

Identification of patients at risk for FU using simple and reliable methods is of clinical relevance. The ADA recommends the combined use of simple tests including pinprick, temperature, vibration and 10 g monofilament perception as well as ankle reflexes for this purpose (11). Our findings suggest that the Neuropad can be included in the screening tests for the prediction of FU. Advantages of the Neuropad are its simplicity, wide availability, high performance for the diagnosis of PN, and high reproducibility (5,12). Moreover, the test can be self-performed and evaluated safely by the patients (13).

This is a cross-sectional study and a casual relationship between the moisture status of the skin of the feet and FU cannot be established. Moreover, although the odds ratio is large, suggesting that there is an association between an abnormal Neuropad response and FU, the confidence intervals are wide and it is necessary to be cautious about the interpretation of the finding.

In summary, dryness of the skin of the feet assessed by the Neuropad test correlates with FU. This finding, if confirmed prospectively, suggests that the Neuropad may be included in the screening tests for the prediction of FU in subjects with diabetes.

ACKNOWLEDGEMENTS

Neuropad tests were supplied by miro
Verbandstoffe.

Disclosures.

None.

REFERENCES

1. Boulton AJM. The diabetic foot: from art to science. The 18th Camillo Golgi lecture. *Diabetologia* 2004;47:1343–1353
2. Quattrini C, Jeziorska M, Malik RA. Small fiber neuropathy in diabetes: clinical consequence and assessment. *Int J Low Extrem Wounds* 2004;3:16-21
3. Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA, Maser RE, Sosenko JM, Ziegler D; American Diabetes Association. Diabetic neuropathies: a statement by the American Diabetes Association. *Diabetes Care* 2005;4:956–962
4. Quattrini C, Jeziorska M, Tavakoli M, Begum P, Boulton AJ, Malik RA. The Neuropad test: a visual indicator test for human diabetic neuropathy. *Diabetologia* 2008;51:1046-1050
5. Papanas N, Giassakis G, Papatheodorou K, Papazoglou D, Monastiriotis C, Christakidis D, Piperidou H, Maltezos E. Sensitivity and specificity of a new indicator test (Neuropad) for the diagnosis of peripheral neuropathy in type 2 diabetes patients: a comparison with clinical examination and nerve conduction study. *J Diabetes Complications* 2007;21:353-358
6. Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. *Diabetologia* 1993;36:150-154
7. Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. *JAMA* 2005;293:217-228
8. Apelqvist J, Bakker K, van Houtum WH, Schaper NC; International Working Group on the Diabetic Foot (IWGDF) Editorial Board. Practical guidelines on the management and prevention of the diabetic foot: based upon the International Consensus on the Diabetic Foot (2007) Prepared by the International Working Group on the Diabetic Foot. *Diabetes Metab Res Rev* 2008;24(Suppl 1):S181-S187
9. Low VA, Sandroni P, Fealey RD, Low PA. Detection of small-fiber neuropathy by sudomotor testing. *Muscle Nerve* 2006;34:57-61
10. Tentolouris N, Marinou K, Kokotis P, Karanti A, Diakoumopoulou E, Katsilambros N. Sudomotor dysfunction is associated with foot ulceration in diabetes. *Diabet Med* 2009;26:302-305
11. Boulton AJ, Armstrong DG, Albert SF, Frykberg RG, Hellman R, Kirkman MS, Lavery LA, Lemaster JW, Mills JL Sr, Mueller MJ, Sheehan P, Wukich DK; American Diabetes Association; American Association of Clinical Endocrinologists: Comprehensive foot examination and risk assessment: a report of the task force of the foot care interest group of the American Diabetes Association, with endorsement by the American Association of Clinical Endocrinologists. *Diabetes Care* 2008;31:1679-1685
12. Papanas N, Papatheodorou K, Papazoglou D, Christakidis D, Monastiriotis C, Maltezos E. Reproducibility of the new indicator test for sudomotor function (Neuropad) in patients with type 2 diabetes mellitus. *Exp Clin Endocrinol Diabetes* 2005;113:577–581
13. Tentolouris N, Achtsidis V, Marinou K, Katsilambros N. Evaluation of the self-administered indicator plaster Neuropad for the diagnosis of neuropathy in diabetes. *Diabetes Care* 2008;31:236-237

Table 1-Demographic and clinical characteristics as well as the association (odds ratio, 95% CI) between the studied parameters with foot ulceration (FU)

	Without FU (N=258)	With FU (N=121)	P
Age (years)	60.0 ± 11.7	63.2 ± 10.2	0.86
Male/female n (%)	130 (50.4)/ 128(49.6)	84(69.4)/37(30.6)	0.001
Type 1/type 2 diabetes n (%)	15 (5.8)/ 243 (94.2)	8 (6.6)/113(93.4)	0.46
Duration of diabetes (years) (median value, IQR)	10.0 (5.0-16.0)	18.0 (10.0-25.0)	<0.001
A1C (%)	7.4 ± 1.6	9.2 ± 2.4	<0.001
VPT (Volts)	21.5 ± 11.6	37.4 ± 12.2	<0.001
VPT ≥ 25 Volts n (%)	85 (32.9)	101 (83.5)	<0.001
NSS (median value, IQR)	4.5 (0.0-6.0)	6.0 (4.0-7.0)	<0.001
NDS (median value, IQR)	2.0 (0.0-5.0)	7.0 (6.0-10.0)	<0.001
NDS ≥ 6 n (%)	62 (24.0)	92 ((76.0)	<0.001
Monofilament insensation n (%)	36 (14.0)	70 (57.9)	<0.001
Neuropathy n (%)	114 (44.2)	114 (94.2)	<0.001
Ankle-brachial pressure index	1.00 ±0.22	0.98 ±0.22	0.050
Peripheral artery disease n (%)	42 (16.3)	31 (25.6)	0.09
Abnormal Neuropad result n (%)	135 (52.3)	115 (95.0)	<0.001
<i>Univariate analysis</i>	<i>Odds ratio</i>	<i>95% CI</i>	
Age (1 year)	1.00	0.98-1.02	0.56
Gender (male vs. female)	1.83	1.14-2.95	0.01
Duration of diabetes (1 year)	1.08	1.05-1.11	<0.001
A1C (1%)	1.32	1.18-1.74	0.002
NSS (1 unit)	1.24	1.13-1.36	<0.001
NDS (1 unit)	1.61	1.45-1.79	<0.001
NDS ≥ 6 vs. < 6	10.7	6.25-18.40	<0.001
VPT (1 Volt)	1.10	1.08-1.13	<0.001
VPT ≥ 25 vs. < 25 Volts	12.23	6.20-22.68	<0.001
Monofilament result (insensation vs. sensation)	8.33	4.18-16.59	<0.001
Neuropad result (abnormal vs. normal)	17.3	7.36-40.8	<0.001
Peripheral artery disease (yes vs. no)	1.84	1.07-3.10	0.02
<i>Multivariate analysis*</i>			
<i>Model 1</i>			
NDS ≥ 6 vs. < 6	6.70	3.31-13.35	<0.001
<i>Model 2</i>			
VPT ≥ 25 vs. < 25 Volts	11.91	6.03-21.86	<0.001
<i>Model 3</i>			
Monofilament result (insensation vs. sensation)	6.40	3.09-13.28	<0.001
<i>Model 4</i>			
Neuropad result (abnormal vs. normal)	16.28	6.27-38.24	<0.001

Data are mean values ± SD unless otherwise indicated. IQR: interquartile range, VPT: vibration perception threshold, NSS: neuropathy symptom score, NDS: neuropathy disability score.

Gender, NDS ≥ 6 vs. < 6, VPT ≥ 25 vs. < 25 Volts, monofilament result (insensation vs. sensation), Neuropad result (abnormal vs. normal), and peripheral artery disease (yes vs. no) were analyzed as categorical variables; all the other variables were analyzed as continuous variables in both univariate and multivariate analysis. *Each one of the models 1-4 were adjusted in addition for age, gender, duration of diabetes, A1C, NSS, and peripheral artery disease status.